Nova Biomedical Enhances Cell Line Development with NanoCellect Acquisition

In a significant move to strengthen its biopharmaceutical capabilities, Nova Biomedical has officially announced the acquisition of certain assets from NanoCellect, a leading provider of microfluidic cell sorting technology. This acquisition is designed to enhance Nova's integrated cell line development workflows, bridging the gap between early development and manufacturing phases in biopharmaceutical processes.

Enhancing Integrated Workflows

The inclusion of NanoCellect’s products, particularly the WOLF G2® cell sorting platform, offers Nova Biomedical an upgraded capability for gentle cell selection and isolation. This technology perfectly complements Nova’s existing Solentim suite for clone generation, verification, and growth analysis. By integrating these systems, Nova aims to provide a streamlined approach to cell line development, which is critical in the fast-paced biopharmaceutical landscape.

By combining cell sorting, individual cell isolation, and high-reliability clone verification, the technologies adopted from NanoCellect empower researchers to expedite their processes significantly. Through this acquisition, Nova Biomedical is not just adding to its portfolio, but also reducing development timelines while improving clonal selection outcomes. This is a pivotal enhancement that facilitates a more cohesive strategy for advancing and manufacturing biopharmaceutical products.

Advanced Analytical Solutions

Also part of Nova Biomedical's extensive portfolio are BioProfile® FLEX2 for metabolite analysis, OsmoTECH® for osmolality measurement, and BioProfile® FAST CDV for cell counting and viability assessment. These analytical solutions play a fundamental role in monitoring cell cultures throughout the bioprocess lifecycle. They ensure critical controls that are necessary from development through production stages.

The integration of NanoCellect’s technologies further reinforces Nova’s commitment to offering a more extensive and interconnected suite of technologies. John Luck, president of Nova Biomedical’s biopharmaceutical division, stated, “NanoCellect provides crucial upstream capabilities to our portfolio, helping us better connect the key stages of cell line development.” He emphasized that by linking cell sorting with cloning isolation and reliable verification alongside analytical checkpoints, customers can identify successful clones more swiftly. This capability helps to optimize clonal selection and improve overall performance during process development and manufacturing.

A Step Towards Differentiated Platforms

This acquisition marks an essential step towards creating a more interconnected and differentiated platform for cell line development and bioprocessing. It aligns with Nova Biomedical’s objective to enhance customer experience and outcomes by providing tools that mean clients can make informed decisions throughout the bioprocess lifecycle.

Who is Nova Biomedical?

Nova Biomedical is a global provider of advanced instruments and analytical solutions serving both biopharmaceutical and clinical markets. Their products support crucial workflows in cell line development, process development, and manufacturing, empowering clients to enhance productivity, product quality, and operational efficiency.

About NanoCellect

On the other hand, NanoCellect specializes in microfluidic cell sorting technologies designed for gentle cell isolation under sterile conditions. Their platforms are widely used in cell line development, individual cell analysis, and cellular therapy research. This acquisition not only strengthens Nova Biomedical’s offerings but also reinforces their position in the biopharmaceutical sector, paving the way for innovative developments in the near future.

In a landscape where speed and efficiency are paramount, Nova Biomedical's strategic steps to integrate NanoCellect's technologies could redefine the workflow of cell line development and bioprocessing in the years to come.